MedTrace Logo

A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

NCT01286831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-06-20

No results posted yet for this study

Summary

The purpose of this study is to characterise the metabolic disposition of radiolabelled GW642444 when administered orally.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

[14C]GW642444

Single 200μg dose of \[14C\]GW642444 given on Day 1.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-18
Primary Completion
2010-07-09
Completion
2010-07-09

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01286831 on ClinicalTrials.gov